LatticeMLS
Menu

Module COAG-06 · Version 1.0

Recognizing Common Bleeding-Disorder Patterns

Use platelet count, PT, aPTT, fibrinogen, and a focused bleeding history together to sort an initial bleeding differential into isolated platelet, isolated PT, isolated aPTT, combined, and normal-screen patterns, then choose a targeted next test without diagnosing from the screen alone.

Your next section

Start section 1

Read without an account. Sign in to save.

Who this module is for

Clinical laboratory scientists and students working coagulation bench or specimen triage who interpret PT, aPTT, platelet count, and fibrinogen results.

Learning objectives

  • Classify isolated platelet, isolated PT, isolated aPTT, combined, and fibrinogen abnormality patterns from a screening result set
  • Recognize common inherited and acquired pattern families that fit each screening pattern without diagnosing a specific disorder from the screen alone
  • Choose a targeted follow-up test based on a specimen and medication review, the bleeding history, and the confirmed pattern

How completion works

Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.

Sources

13 sources

  1. 1. Clinical and Laboratory Standards Institute. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test, 3rd ed., CLSI guideline H47. Wayne, PA: CLSI; 2023.

    Source note · consensus standard

  2. 2. Clinical and Laboratory Standards Institute. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays, 6th ed., CLSI guideline H21. Wayne, PA: CLSI; 2024.

    Source note · consensus standard

  3. 3. 42 CFR 493.1253, Establishment and verification of performance specifications.

    Source note · federal regulation

  4. 4. College of American Pathologists. Hematology and Coagulation Checklist, sample checklist, current web edition.

    Source note · accreditation standard

  5. 5. James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances. 2021;5(1):280-300.

    Source note · professional society guidance

  6. 6. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158.

    Source note · professional society guidance

  7. 7. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and Haemostasis. 2001;86:1327-1330.

    Source note · consensus standard

  8. 8. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. Journal of Intensive Care. 2014;2(1):15.

    Source note · peer-reviewed literature

  9. 9. Branchford BR, Di Paola J. Making a diagnosis of VWD. Hematology American Society of Hematology Education Program. 2012;2012:161-167.

    Source note · peer-reviewed literature

  10. 10. Favresse J, Lippi G, Roy PM, et al. Isolated prolongation of activated partial thromboplastin time: not just bleeding risk. Journal of Clinical Medicine. 2020;9:310.

    Source note · peer-reviewed literature

  11. 11. Tripodi A, Ageno W, Ciaccio M, et al. Position paper on laboratory testing for patients on direct oral anticoagulants. Blood Transfusion. 2018;16:316-324.

    Source note · professional society guidance

  12. 12. Favaloro EJ, Lippi G. Direct oral anticoagulant interference in hemostasis assays. Seminars in Thrombosis and Hemostasis. 2021;47:806-817.

    Source note · peer-reviewed literature

  13. 13. Mangla A, Hamad H. Factor XIII Deficiency. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; updated 2025.

    Source note · peer-reviewed literature